AA Amyloidosis: Comprehensive Disease Characteristics Research Report

1. Disease Information

Overview. AA amyloidosis (amyloid A amyloidosis; historically "secondary" or "reactive" systemic amyloidosis) is an acquired, potentially fatal complication of chronic inflammatory, infectious, or autoinflammatory disease in which the acute-phase reactant serum amyloid A (SAA) is proteolytically cleaved, misfolds, and deposits extracellularly as insoluble cross-β-sheet AA amyloid fibrils in multiple organs, most severely the kidney. It is one of the ~40 recognized human systemic amyloidoses classified by fibril precursor protein, and clinically it is dominated by progressive proteinuria and renal failure (PMC11219434, "AA Amyloidosis: A Contemporary View," Mirioglu et al., Curr Rheumatol Rep 2024;26:248-259, PMID:38568326).

Key identifiers: - MONDO: MONDO:0019439 - Orphanet: ORPHA:85445 (also grouped under ORPHA:69, Amyloidosis) - ICD-10-CM: E85.3 (Secondary systemic amyloidosis) - OMIM (related/hereditary form): A rare autosomal-dominant hereditary form driven by an SAA1 promoter mutation has been described (Kidney International 2021; distinct from the acquired/reactive form that dominates clinical practice) — see Section 4/9. The classic acute-phase-reactant gene entry is OMIM 104750 (SAA1). - MeSH: Amyloidosis (D000686); the AA-specific concept is indexed under "Amyloidosis" with SAA protein subheading. - UniProt:* P0DJI8 (SAA1_HUMAN), P0DJI9 (SAA2_HUMAN)

Synonyms: Secondary amyloidosis; reactive systemic amyloidosis; inflammatory amyloidosis; amyloid A (AA) amyloidosis; SAA amyloidosis.

Data provenance. Most quantitative disease-level knowledge (incidence, organ-involvement frequencies, survival statistics) derives from aggregated multicenter cohort studies and national amyloidosis referral centers (e.g., the UK National Amyloidosis Centre, French multicenter renal-transplant cohorts, and large FMF registries) rather than individual EHR mining — this is a rare disease with concentrated expert-center case ascertainment (PMID:38568326; French AJKD/AJT transplant cohort studies below).

2. Etiology

2a. Disease Causal Factors

AA amyloidosis is fundamentally a disease of sustained inflammation: any condition producing chronically or recurrently elevated SAA for a sufficient duration and concentration can, in a susceptible host, trigger fibrillogenesis. Recognized etiologic categories (PMID:38568326; PMC11219434):

Chronic inflammatory arthritides (~60-70% of cases in industrialized nations): rheumatoid arthritis (historically the single largest cause), ankylosing spondylitis, psoriatic arthritis, juvenile idiopathic arthritis.
Autoinflammatory (periodic fever) syndromes: familial Mediterranean fever (FMF, MEFV), TNF receptor-associated periodic syndrome (TRAPS, TNFRSF1A), cryopyrin-associated periodic syndromes/CAPS (NLRP3, includes Muckle-Wells syndrome), mevalonate kinase deficiency/hyper-IgD syndrome (MVK).
Chronic infections: tuberculosis, leprosy, chronic osteomyelitis, bronchiectasis, chronic pyelonephritis, decubitus ulcers, IV drug use with recurrent skin/soft-tissue infection — the dominant cause in low/middle-income countries.
Inflammatory bowel disease: Crohn's disease (more than ulcerative colitis).
Vasculitides: giant cell arteritis, Takayasu arteritis, polyarteritis nodosa, granulomatosis with polyangiitis.
Primary immunodeficiencies: common variable immunodeficiency, hypo/agammaglobulinemia (recurrent infection as the proximate driver).
Malignancy (uncommon): renal cell carcinoma, Hodgkin lymphoma, Castleman disease.
Idiopathic: up to ~20-25% of cases have no identifiable overt inflammatory trigger.

Direct quote (mechanistic causal statement): "the exact mechanisms remain incompletely understood" but "inflammatory cytokines—particularly interleukin-6—stimulate hepatic production of serum amyloid A (SAA). Sustained elevation of plasma SAA concentrations leads to aggregation into fibrillar deposits" (Westermark GT, Fändrich M, Westermark P. Annu Rev Pathol 2015;10:321-44, PMID:25387054).

2b. Risk Factors

Genetic risk factors: - SAA1 allelic variation — the single strongest documented genetic modifier. Human SAA1 has five common coding-region alleles (SAA1.1–SAA1.5, differing at codons 52 and 57: alpha=Val52, beta=Val57, gamma=Ala52/Ala57). SAA1.1 predominates in European populations and its homozygosity is associated with increased amyloidosis risk in RA and FMF; SAA1.3 homozygosity confers elevated risk in Japanese populations. Population allele-frequency differences (SAA1.1-dominant in Caucasians vs. near-equal SAA1.1/1.3/1.5 distribution in Japanese cohorts) partly explain geographic variation in amyloidosis penetrance (GeneCards SAA1; PMID:12687559, PMID:15018633, PMC3577815, PMC11535276). - MEFV genotype in FMF — homozygosity for the p.Met694Val (M694V) missense variant is the strongest single MEFV risk allele for renal AA amyloidosis, particularly documented in North African Jewish FMF cohorts; combined SAA1α/α + M694V/M694V homozygosity substantially compounds risk (PMID:12687559). - Country/ethnicity of residence — identified in FMF cohorts as a risk factor for amyloidosis independent of MEFV genotype and disease duration, implicating additional genetic-background or environmental modifiers (PMC11219434). - Rare autosomal-dominant hereditary SAA1 promoter mutation — a single-nucleotide promoter variant (chr11:18287683 T>C, hg19) linked to the amyloidogenic SAA1.1 haplotype doubles basal SAA1 promoter activity, producing chronically elevated baseline SAA (without other acute-phase protein elevation) and autosomal-dominant AA amyloidosis in the absence of an inflammatory trigger (LOD score >5 across 12 affected/6 unaffected relatives) (Kidney Int 2021, PMID pending indexing — ScienceDirect S0085-2538(21)00867-X).

Environmental / demographic risk factors: - Obesity — an independently identified susceptibility factor for idiopathic AA amyloidosis; obese/idiopathic-AA patients are older and more obese than FMF- or RA-associated AA cases (Amyloid 2018, PMID:29364741). Adipose tissue itself expresses SAA1/SAA2 (as an "adipokine"), correlating with BMI and contributing to chronic low-grade systemic inflammation independent of hepatic SAA (PLOS Medicine 2006, PMID:16737350). - Older age at disease onset/diagnosis (median historically ~50 years, more recent cohorts report up to 70), reflecting cumulative inflammatory burden and improved recognition of idiopathic/obesity-associated cases (PMID:38568326). - Male sex — slightly increased representation in most cohorts. - Duration and control of the underlying inflammatory disease — untreated/undertreated chronic inflammation (e.g., colchicine-noncompliant FMF) is the dominant modifiable environmental/behavioral risk factor. - Socioeconomic/geographic setting — infection-driven AA amyloidosis predominates where chronic infections (TB, leprosy, osteomyelitis) are more prevalent (developing regions); rheumatic-disease-driven AA predominates in industrialized nations with better infection control.

2c. Protective Factors

Colchicine compliance in FMF is the best-documented protective intervention: in a cohort of 960 FMF patients, the cumulative rate of proteinuria at 11 years was 1.7% in colchicine-compliant patients vs. 48.9% in non-compliant patients (PMC11219434, citing FMF colchicine outcome studies).
Effective suppression of the underlying inflammatory disease by any modality (biologics, DMARDs, anti-infective therapy) that durably normalizes SAA is protective against amyloid progression and, when applied early, can permit amyloid regression.
No specific protective genetic variants (e.g., an SAA1 "resistant" allele analogous to APOE2 in Alzheimer disease) are firmly established, though non-SAA1.1/1.3 genotypes appear less amyloidogenic in the populations studied.

2d. Gene-Environment Interactions

The clearest documented gene-environment interaction is the combination of amyloidogenic SAA1 genotype (SAA1α/α or SAA1.3 homozygosity) with a chronic inflammatory driver (FMF genotype severity, RA disease duration, or obesity-associated adipose inflammation): neither the SAA1 risk allele alone nor inflammation alone reliably produces amyloidosis — sustained elevation of SAA to a critical, prolonged concentration in a host carrying an amyloidogenic SAA1 haplotype is required (PMC11219434; PMID:29364741 for the obesity+SAA1 interaction specifically). Ethnic/geographic background further modulates this interaction beyond MEFV genotype alone in FMF cohorts, suggesting unidentified additional genetic or environmental modifiers (PMC11219434).

3. Phenotypes

AA amyloidosis phenotypes are best organized by organ system; renal disease dominates the clinical picture in >90% of patients at presentation.

Renal (most frequent; ~90% at presentation)

Proteinuria — HP:0000093 (Proteinuria); often nephrotic-range.
Nephrotic syndrome — HP:0000100 (Nephrotic syndrome); reported in >50-63% of patients (PMC11219434; PMID:17714761 reports 63.1%).
Progressive chronic kidney disease / renal insufficiency — HP:0012622 (Chronic kidney disease); ~75% of patients show renal insufficiency at some point (PMID:17714761).
Acute kidney injury — HP:0001919 (Acute kidney injury), seen in the rare "amyloid storm" presentation.
Renal failure / end-stage kidney disease — HP:0000083 (Renal insufficiency) progressing to ESKD; ~10% present already in kidney failure.
Nephrogenic diabetes insipidus — HP:0009806, reported with tubulointerstitial-predominant deposition patterns.
Onset: variable, typically adult-onset, insidious over months-to-years except the acute "amyloid storm" variant in FMF (days-to-weeks).
Severity/progression: progressive without treatment; a landmark large study found untreated 5-year renal survival poor.

Systemic/Constitutional

Weight loss — HP:0001824.
Fatigue/weakness — HP:0025406 / HP:0001324 (Muscle weakness) — reported as one of the most common overall manifestations.
Peripheral edema — HP:0000969, secondary to nephrotic-range proteinuria and hypoalbuminemia.
Orthostatic hypotension — HP:0001278.

Hepatosplenic

Hepatomegaly — HP:0002240.
Splenomegaly — HP:0001744.
Clinically these are frequent radiographic/pathologic findings but usually functionally silent; elevated alkaline phosphatase (HP:0003155, Elevated alkaline phosphatase) is a marker of hepatic amyloid activity rather than hepatic failure.

Gastrointestinal (~30%)

Chronic diarrhea — HP:0002014 (Diarrhea), often refractory to standard antidiarrheal treatment; the predominant GI symptom.
Malabsorption — HP:0002024.
Gastrointestinal hemorrhage — HP:0002239.
Macroglossia — HP:0000158 (occurs, but far less frequent than in AL amyloidosis — an important differentiating feature).
Rarely: intestinal pseudo-obstruction.

Cardiac (relatively uncommon compared with AL amyloidosis)

Cardiomyopathy / increased left ventricular wall thickness — HP:0001635 (Congestive heart failure), HP:0001712 (Cardiomyopathy); left ventricular wall thickness >12 mm (absent hypertension) suggests amyloid infiltration, but overt heart failure is uncommon relative to AL/ATTR amyloidosis (PMC11219434) — an important differential-diagnosis clue.

Neurologic

Peripheral neuropathy — HP:0009830 — infrequent (contrasts with AL amyloidosis, where it is common).
Carpal tunnel syndrome — HP:0100039 — infrequent in AA compared with AL/ATTR forms.

Endocrine

Adrenal insufficiency, hypothyroidism (secondary to amyloid infiltration of endocrine glands) — reported but uncommon.

Laboratory abnormalities

Elevated serum amyloid A (SAA) and C-reactive protein (CRP) — the central biomarkers, tracked longitudinally as surrogates of disease activity and amyloid regression risk.
Hypoalbuminemia, dyslipidemia (secondary to nephrotic syndrome).
Elevated alkaline phosphatase as above.

The "Amyloid Storm" phenotype (FMF-specific, rare)

A distinct acute presentation: "acute illness, marked by substantial proteinuria, elevated inflammatory markers, and rapid progression to kidney failure within weeks," typically triggered by an infection or other acute inflammatory insult in FMF patients (PMC11219434). Age of onset: any age in established FMF; onset pattern: acute/subacute (days-weeks) — distinct from the otherwise chronic, insidious natural history.

Quality-of-life impact

No AA-amyloidosis-specific validated QoL instrument was identified in this search; QoL burden is dominated by the consequences of nephrotic syndrome (fatigue, edema, dietary restriction), chronic diarrhea, and progression to dialysis-dependence, each independently associated with substantial functional impairment per general CKD/dialysis QoL literature (not amyloid-specific; general inference, flagged as such).

4. Genetic/Molecular Information

Causal/Contributory Genes

AA amyloidosis is not a single-gene Mendelian disease in its usual (acquired/reactive) form — it is a complex trait arising from an inflammatory disease acting on a genetically variable SAA/inflammasome background. The relevant genes are:

SAA1 (HGNC:10513; Gene ID 6288; chr11p15.1; OMIM *104750) — encodes serum amyloid A1, the dominant fibril-forming precursor isoform in AA deposits.
SAA2 (HGNC:10514; chr11p15.1) — a closely related, ~95%-homologous acute-phase isoform; N-terminal SAA2-derived peptide (SAA2-15) has been localized specifically within Congo red-positive amyloid regions by imaging mass spectrometry, implicating it directly in fibril nucleation (PMC9565386).
MEFV (HGNC:6998; chr16p13.3; encodes pyrin) — the causal gene of familial Mediterranean fever, the single most important monogenic upstream trigger disease for AA amyloidosis worldwide. Pyrin is a component of the pyrin inflammasome, driving caspase-1 activation and IL-1β production upon dysregulation.
TNFRSF1A (TRAPS), NLRP3 (CAPS/Muckle-Wells), MVK (hyper-IgD/mevalonate kinase deficiency) — the other major monogenic autoinflammatory "upstream trigger" genes, each conferring variable AA amyloidosis risk (see Section 9).

Pathogenic Variants

SAA1 alleles (not classically "pathogenic variants" in the ACMG sense, but disease-modifying common polymorphisms): SAA1.1 (Val52/Val57, "alpha"), SAA1.2, SAA1.3 (predominant in Japanese populations), SAA1.4, SAA1.5 (Ala52/Ala57, "gamma") — differ by 1-2 amino acids at codons 52/57. Functional consequence of the amyloidogenic alleles: SAA1.1 shows "increased susceptibility of serum amyloid A 1.1 to degradation by MMP-1," generating the amyloidogenic 76-residue AA fragment more readily (PMC11219434).
MEFV p.Met694Val (M694V) — classified pathogenic/high-penetrance for severe FMF phenotype and amyloidosis risk (ClinVar); homozygosity is the key genotype-amyloidosis association. Other MEFV variants (p.M680I, p.M694I) are more common in some Arab populations and associated with lower amyloidosis risk.
SAA1 promoter regulatory variant chr11:18287683 T>C (hg19), on the amyloidogenic SAA1.1 haplotype background — a gain-of-expression (not missense) mechanism causing autosomal-dominant hereditary AA amyloidosis via chronically doubled basal SAA1 transcription (Kidney Int 2021).
Somatic vs. germline: All AA-amyloidosis-relevant variants (SAA1 allelic variants, MEFV, TNFRSF1A, NLRP3, MVK) are germline; there is no recognized somatic/clonal component (this is the key biological distinction from AL amyloidosis, which arises from a somatic clonal plasma-cell/B-cell disorder).
Allele frequency: SAA1.1 is the majority allele in European-ancestry populations (gnomAD/1000 Genomes frequency data were not independently re-derived in this search but are cited as dominant in Caucasian cohorts per GeneCards/PMC3577815); MEFV carrier frequency is high (up to 1 in 5-7) in Mediterranean-basin populations (Sephardic/North African Jews, Armenians, Turks, Arabs) consistent with FMF's status as one of the most common autosomal recessive diseases in those groups (general FMF epidemiology, not independently re-verified here).

Functional Consequences / Molecular Mechanism of Misfolding

The 122-amino-acid, ~12 kDa SAA1/SAA2 apolipoprotein precursor undergoes proteolytic cleavage by matrix metalloproteinases (MMPs) to a ~76-amino-acid AA fragment. This cleavage, combined with local physicochemical factors (acidic pH, elevated temperature, heparin/heparan sulfate proteoglycans), increases resistance to further proteolysis and promotes conformational conversion to a cross-β-sheet amyloidogenic state. Fibril formation is nucleation-dependent: once a fibrillar nucleus forms, it "recruits and catalyzes the conversion of native molecules" in a self-propagating cascade (PMID:25387054). Cofactors implicated in fibril stabilization/deposition include serum amyloid P component (SAP), heparan sulfate, and apolipoproteins (PMC11219434). Cryo-EM has resolved AA fibril core structures directly from patient tissue, showing "species complementarity" of the pathological fold (PMC6405766).

Modifier Genes

SAA1 itself functions as the principal modifier of amyloidosis risk in patients with an inflammatory trigger disease (FMF, RA) — i.e., it modifies penetrance/severity rather than causing disease alone.
MICA polymorphisms have also been reported as a modifying factor for amyloidosis risk in FMF alongside MEFV and SAA1 (PMID:15018633).

Epigenetic Information

No AA-amyloidosis-specific epigenetic (DNA methylation/histone) studies were identified in this search; SAA transcriptional induction is primarily driven by classical cytokine-responsive transcription factor activation (NF-κB, C/EBP) downstream of IL-1β/IL-6/TNF-α signaling rather than a documented disease-specific epigenetic mechanism. Flagged as not available/not established for this disease.

Chromosomal Abnormalities

None recognized; AA amyloidosis is not associated with aneuploidy, translocations, or copy-number disorders. Not applicable.

5. Environmental Information

Environmental/occupational factors: No specific toxin, radiation, or occupational chemical exposure is established as a direct AA amyloidosis trigger; risk operates indirectly through chronic inflammatory or infectious disease (e.g., occupational exposures causing chronic osteomyelitis or silicosis-associated inflammation) rather than a direct toxic mechanism. ECTO term candidate: exposure to chronic infection/inflammatory stimulus (general, disease-mediated rather than a discrete chemical exposure).
Lifestyle factors: Obesity is the best-documented lifestyle-adjacent risk factor (Section 2b), acting through adipose-tissue SAA production and chronic low-grade systemic inflammation (PMID:16737350, PMID:29364741). Poor medication adherence (e.g., colchicine non-compliance in FMF) is the principal modifiable behavioral risk factor for progression (PMC11219434).
Infectious agents: Chronic bacterial infections are direct etiologic triggers rather than "risk factors" per se — most importantly Mycobacterium tuberculosis (chronic pulmonary/extrapulmonary TB), Mycobacterium leprae (leprosy), and pyogenic osteomyelitis pathogens (commonly Staphylococcus aureus). These remain the dominant AA amyloidosis triggers in resource-limited settings where chronic untreated infection is more prevalent (PMC11219434). NCBI Taxonomy: Mycobacterium tuberculosis (NCBITaxon:1773); Mycobacterium leprae (NCBITaxon:1769); Staphylococcus aureus (NCBITaxon:1280).

6. Mechanism / Pathophysiology

Causal Chain (Trigger → Clinical Manifestation)

Trigger: Chronic inflammatory, infectious, or autoinflammatory disease (Section 2a) produces sustained elevation of pro-inflammatory cytokines.
Cytokine-driven hepatic SAA overproduction: IL-6 (primary driver), IL-1β, and TNF-α stimulate hepatocyte transcription and secretion of SAA1/SAA2 as acute-phase apolipoproteins, normally associated with HDL. GO term: GO:0006953 (acute-phase response); GO:0070669 (response to interleukin-6); molecular players: IL6 (HGNC:6018), IL1B (HGNC:5992), TNF (HGNC:11892).
Sustained pathologic SAA elevation: Prolonged (not merely transient acute-phase) elevation to critical plasma concentrations is required — this is the rate-limiting upstream lesion distinguishing amyloidogenic from ordinary acute-phase physiology.
Proteolytic cleavage / misfolding: Extracellular/tissue proteases (notably MMPs, e.g., MMP-1) cleave the 122-aa SAA precursor to a ~76-aa AA fragment; the amyloidogenic SAA1.1/SAA1.3 alleles are preferentially susceptible to this cleavage. GO: GO:0006508 (proteolysis); cellular process: GO:0034629 (cellular protein-containing complex localization) is less specific — better: GO:1990830 or general "amyloid fibril formation" GO:1990000 (amyloid fibril formation).
Nucleation-dependent fibrillogenesis: Misfolded AA fragments adopt a cross-β-sheet conformation; nucleation seeds recruit and convert additional native/cleaved SAA molecules in a self-propagating cascade, stabilized by cofactors (serum amyloid P component, heparan sulfate proteoglycans, apolipoproteins).
Tissue deposition: Extracellular AA fibril deposits accumulate first in perivascular/mesangial spaces, especially in kidney (glomerular mesangium and capillary walls), spleen (red/white pulp), liver (space of Disse/portal areas), and adrenal glands.
Organ dysfunction: Glomerular amyloid deposition disrupts the filtration barrier → proteinuria/nephrotic syndrome → progressive nephron loss → CKD/ESKD. Analogous architectural disruption underlies hepatosplenic and GI dysfunction.

Cellular Processes and Cell Types Involved

Hepatocytes (CL:0000182) — primary site of SAA biosynthesis under cytokine stimulation.
Macrophages (CL:0000235) — implicated in local AA fibril processing/propagation; notably, AA amyloidosis has been experimentally shown transferable via peripheral blood monocytes in animal models, supporting a monocyte/macrophage role in disease transmission of the amyloid-enhancing seed (PLOS ONE, PMC3308).
Glomerular mesangial cells (CL:0000650) and glomerular endothelial cells (CL:0002144) — sites of amyloid deposition and secondary injury in the kidney.
Adipocytes (CL:0000136) — a peripheral, non-hepatic source of SAA in obesity-associated idiopathic AA amyloidosis.

Protein Dysfunction

SAA/AA amyloid pathology is a gain-of-toxic-aggregation process rather than loss-of-function: native SAA retains its lipid-transport/immune-signaling roles, but a fraction of the chronically elevated, proteolytically processed pool undergoes conformational conversion to insoluble, protease-resistant β-sheet fibrils that are cytotoxic and architecturally disruptive to tissue. UniProt: P0DJI8/P0DJI9 (SAA1/SAA2); structural fold: cross-β amyloid, resolved by cryo-EM directly from ex vivo patient fibrils (PMC6405766).

Metabolic Changes

SAA functions physiologically as a component of HDL particles influencing lipid transport; chronic overproduction and diversion into amyloid fibrils is associated with dyslipidemia (secondary largely to nephrotic syndrome rather than a primary SAA lipid-metabolism defect). SAA is now also recognized as an obesity-associated adipokine, directly linking adipose tissue inflammation, lipid metabolism, and systemic SAA elevation (PMID:16737350).

Immune System Involvement

Central and causal: SAA is itself an acute-phase innate-immune protein with roles in leukocyte chemotaxis and antibacterial defense; its pathologic overproduction is a direct consequence of dysregulated innate immune/inflammasome signaling (IL-1β/pyrin axis in FMF; NLRP3 inflammasome in CAPS). The disease is thus best framed as a maladaptive consequence of chronic innate immune activation, not autoimmunity in the classical adaptive-immune sense, though it frequently complicates autoimmune/rheumatic disease (RA).

Tissue Damage Mechanisms

Amyloid deposits cause tissue injury through direct structural/architectural disruption (glomerular filtration barrier, hepatic sinusoidal architecture, splenic parenchyma) and possible direct cytotoxicity of prefibrillar oligomeric SAA species (analogous to other amyloidoses), rather than through oxidative stress or classical ischemic mechanisms as the primary driver.

Molecular Profiling / Advanced Technologies

Proteomics: Laser-microdissection/mass spectrometry (LMD-MS) of Congo-red-positive tissue is now the diagnostic and mechanistic gold standard for confirming AA (vs. AL, ATTR, or other) fibril composition, identifying the AA-specific 76-residue N-terminal fragment signature; achieves >99% subtype-identification accuracy where available (PMC11219434).
Imaging mass spectrometry: Localized the N-terminal SAA2-derived peptide SAA2-15 specifically within Congo-red-positive amyloid regions, directly implicating this fragment in fibril core formation (PMC9565386).
Cryo-EM: Solved ex vivo AA fibril core structures directly from patient-derived tissue, revealing species-specific structural polymorphism ("species complementarity") (PMC6405766).
Single-cell/spatial transcriptomic and multi-omic human AA amyloidosis-specific datasets were not identified in this search (contrast with the feline model, Section 14/15, where multi-omic data do exist) — flagged as a gap, likely reflecting AA amyloidosis's rarity and tissue-biopsy-based (rather than fresh-tissue -omics) diagnostic workflow in humans.

7. Anatomical Structures Affected

Organ level

Primary: Kidney (UBERON:0002113) — nearly universal involvement, clinically dominant.
Secondary: Liver (UBERON:0002107), spleen (UBERON:0002106), adrenal gland (UBERON:0002369) — "readily accessible" sites classically demonstrated by SAP scintigraphy; gastrointestinal tract (UBERON:0005409/intestine) — clinically significant in ~30%; heart (UBERON:0000948) — infrequent but prognostically important when present; thyroid gland (UBERON:0002046) — occasionally involved.
Body systems: renal/urinary system, gastrointestinal system, hepatobiliary system, endocrine system, and (less often) cardiovascular and peripheral nervous systems.

Tissue and cell level

Kidney: glomerular mesangium and capillary basement membrane (mesangial and subendothelial amyloid), with a distinct tubulointerstitial-predominant deposition pattern seen in some cases producing milder proteinuria but nephrogenic diabetes insipidus.
Liver: perisinusoidal (space of Disse) deposition.
Spleen: deposition in both red and white pulp regions.
Blood vessel walls — perivascular amyloid deposition is a common early feature across organs.

Subcellular level

Amyloid is an extracellular deposit (GO Cellular Component: GO:0005576, extracellular region), not an intracellular/organellar pathology — distinguishing it mechanistically from intracellular proteinopathies. Electron microscopy shows "rigid, randomly oriented, unbranched fibrils with a thickness of 8-12 nm," distinguishing AA (and other systemic) amyloid from fibrillary glomerulonephritis (15-20 nm fibrils) and immunotactoid glomerulonephritis (30-60 nm microtubules) (PMC11219434).

Localization

Deposition is typically bilateral/systemic rather than lateralized, consistent with a circulating precursor protein depositing wherever local tissue conditions (vascularity, extracellular matrix composition) favor fibril nucleation and growth.

8. Temporal Development

Onset

Adult-onset in the great majority of acquired/reactive cases; median diagnosis age historically ~50 years, with more recent cohorts reporting up to age 70, reflecting an aging population with better-controlled acute inflammatory disease but cumulative burden and rising idiopathic/obesity-associated cases (PMC11219434).
Onset in childhood/adolescence occurs specifically in the context of pediatric-onset autoinflammatory disease (FMF, CAPS, TRAPS, hyper-IgD syndrome) — e.g., pediatric renal AA amyloidosis reported in children with hyper-IgD syndrome/MVK deficiency (PMC4044039).
Onset pattern: typically insidious/chronic (progressive proteinuria over months to years); the "amyloid storm" variant in FMF is a distinct acute presentation evolving over days-to-weeks.

Progression

Disease course: progressive and cumulative without effective control of the underlying inflammatory driver; amyloid deposits are not spontaneously resorbed under ongoing inflammatory stimulation.
Rate: variable, dependent on the degree and duration of SAA elevation; the eprodisate RCT quantified a "mean rate of decline in creatinine clearance" of 15.6 mL/min/1.73m²/year in untreated (placebo) progression vs. 10.9 with eprodisate (PMID:17554116/NEJM 2007), giving a concrete natural-history progression benchmark.
Stages: proteinuria → nephrotic syndrome → progressive CKD → end-stage kidney disease requiring renal replacement therapy; this renal staging sequence is the disease's principal natural-history framework (no formal AJCC-style staging system exists for AA amyloidosis specifically).

Patterns

Remission/regression: Amyloid deposit regression (documented histologically and by SAP scintigraphy) is achievable when SAA is durably suppressed to near-normal levels by treatment of the underlying disease — "decreased [SAA] levels have been consistently associated with the regression of amyloid deposition, improved organ function, and reduced mortality" (PMC11219434). This is a critically important and clinically actionable natural-history feature.
Critical treatment window: Treatment is explicitly time-sensitive — "delayed control of the inflammation cannot prevent the development of amyloid fibril deposits" (PMC11219434), i.e., once substantial fibril deposition and organ damage has occurred, later cytokine suppression halts but does not reliably reverse structural damage (though biochemical/histologic regression is possible for still-active deposits).

9. Inheritance and Population

Epidemiology

Incidence: ~1-2 cases per million person-years in European cohorts (likely underestimated in resource-limited settings with less biopsy access) (PMC11219434).
Autopsy-based incidence: 0.50-0.86% in Western autopsy series (higher than clinically diagnosed rates, implying substantial underdiagnosis).
Relative frequency among amyloidoses: AA amyloidosis now represents only 2.9% of all amyloidosis cases in contemporary Western referral cohorts, a marked decline from historical rates, attributed to improved control of RA and other chronic inflammatory disease with modern biologics (PMC11219434).
Renal amyloidosis composition: AA amyloidosis accounts for ~7% of biopsy-proven renal amyloidosis cases in some series (vs. AL amyloidosis as the dominant renal amyloid type in industrialized settings).

Inheritance pattern (for the genetic-trigger diseases)

AA amyloidosis itself is not inherited as a single Mendelian trait in its usual form, but its principal monogenic upstream triggers are: - FMF (MEFV): autosomal recessive (HP:0000007) — the classic and most important genetic driver of AA amyloidosis worldwide. - TRAPS (TNFRSF1A): autosomal dominant (HP:0000006). - CAPS (NLRP3): autosomal dominant. - Hyper-IgD/mevalonate kinase deficiency (MVK): autosomal recessive. - Rare hereditary SAA1-promoter-driven AA amyloidosis (Kidney Int 2021): autosomal dominant, LOD score >5, full segregation in 12 affected/6 unaffected relatives — a novel, non-MEFV route to hereditary AA amyloidosis via constitutive SAA1 overexpression rather than an inflammasome defect.

Penetrance / Expressivity by trigger disease

TRAPS and CAPS: amyloidosis incidence ~25% of affected individuals.
Muckle-Wells syndrome (CAPS subtype) specifically: >25% of patients show elevated serum amyloid and at least 25% develop overt amyloidosis.
Hyper-IgD syndrome/MKD: <5% develop amyloidosis, "perhaps because the disease often ameliorates spontaneously in early adulthood" (search result summary of PMC4707170 and related literature).
FMF: amyloidosis penetrance is strongly genotype- and geography-dependent (M694V homozygosity + SAA1α/α + country of residence), and is dramatically reduced by colchicine compliance (1.7% vs. 48.9% cumulative proteinuria at 11 years, compliant vs. non-compliant) — a striking real-world demonstration of environmentally-modifiable penetrance.
Founder effects / population-specific mutations: MEFV M694V shows population-specific enrichment (e.g., North African Jewish FMF cohorts); FMF carrier frequency is markedly elevated in Mediterranean-basin populations (Sephardic and North African Jews, Armenians, Turks, Arabs) consistent with founder-effect population genetics of FMF generally.
Consanguinity: relevant to FMF (autosomal recessive) penetrance in high-consanguinity Mediterranean-basin populations, though not independently re-verified with primary data in this search.

Population Demographics

Affected populations: Highest FMF-associated AA amyloidosis burden in Mediterranean-basin/Sephardic Jewish, Armenian, Turkish, and Arab populations owing to high MEFV carrier frequency; broader RA/infection-driven AA amyloidosis occurs across all populations, weighted toward regions with higher chronic infectious disease burden (tuberculosis, leprosy, osteomyelitis) in developing countries.
Geographic distribution: Global, but etiologic mix varies strongly by region as above (infection-dominant in low/middle-income countries vs. rheumatic-disease-dominant in high-income countries).
Sex ratio: slight male predominance reported in several cohorts.
Age distribution: predominantly older adults in acquired/idiopathic and RA-associated disease; pediatric and young-adult cases cluster in the monogenic autoinflammatory-syndrome-driven subset.

10. Diagnostics

Clinical/laboratory tests

Serum amyloid A (SAA) and C-reactive protein (CRP) — key biomarkers for both diagnosis-adjacent risk stratification and (critically) longitudinal monitoring of treatment response and amyloid regression/progression risk. LOINC codes for SAA and CRP exist in standard laboratory ontologies (not individually re-verified here).
24-hour urine protein / urine protein-creatinine ratio — quantifies nephrotic-range proteinuria.
Serum creatinine / estimated GFR — tracks renal function decline (the primary outcome measure in the pivotal eprodisate trial).
Serum albumin — reflects nephrotic-syndrome severity.

Tissue diagnosis (gold standard)

Biopsy with Congo red staining, showing apple-green birefringence under polarized light, is the definitive diagnostic method for amyloid of any type. Immunohistochemistry with anti-AA antibody is then required to subtype the fibril as AA (vs. AL, ATTR, etc.) — "in AA amyloidosis, only the AA [antibody] is positive."
Less invasive biopsy sites: abdominal/periumbilical subcutaneous fat pad aspiration and minor salivary gland biopsy — combined sensitivity 77-89%, allowing avoidance of organ biopsy in many cases.
Renal biopsy remains definitive when renal involvement dominates, with electron microscopy showing the characteristic 8-12 nm randomly oriented fibrils.
Laser microdissection + mass spectrometry (LMD-MS) — the modern proteomic gold standard for unambiguous fibril-protein subtyping (>99% accuracy where available, though costly and limited in global availability).
Immunoelectron microscopy — high sensitivity/specificity, limited by expertise availability.

Imaging

123I-labeled serum amyloid P (SAP) component scintigraphy — historically the premier whole-body amyloid-burden imaging modality, "most useful in AA amyloidosis because the major sites of deposition (liver, kidneys, spleen, and adrenal glands) are readily accessible to the imaging agent," with sensitivity up to 90%; performed at specialized centers (London, Paris) but unavailable in the United States because the reagent (human-derived SAP) cannot undergo the required viral inactivation for US regulatory approval.
Echocardiography and cardiac MRI — assess for (uncommon but prognostically important) cardiac involvement; late/diffuse subendocardial gadolinium enhancement on CMR is a hallmark of amyloid cardiac infiltration generally (not AA-specific).

Genetic testing

MEFV sequencing — indicated in any patient with a Mediterranean-basin ancestry background or clinical FMF phenotype, particularly to confirm M694V zygosity given its strong amyloidosis-risk association.
TNFRSF1A, NLRP3, MVK sequencing — indicated when clinical features suggest TRAPS, CAPS, or hyper-IgD syndrome respectively.
SAA1 genotyping (research/specialized use) — informative for amyloidosis-risk stratification in known FMF/RA patients, though not yet standard-of-care clinical testing.
No standard clinical gene panel specific to "AA amyloidosis risk" as a discrete product was identified; genetic testing in practice is organized around the autoinflammatory-disease gene panels (periodic fever syndrome panels covering MEFV, TNFRSF1A, NLRP3, MVK, and related genes).

Differential diagnosis

Must be distinguished from AL (light-chain) amyloidosis (the other major systemic amyloidosis, more likely to show cardiac involvement, peripheral neuropathy, macroglossia, and carpal tunnel syndrome — features relatively uncommon in AA amyloidosis), hereditary ATTR amyloidosis, and other renal-biopsy differentials including fibrillary glomerulonephritis and immunotactoid glomerulonephritis (distinguished by fibril diameter on EM as above).

Screening

No population-level newborn or carrier screening program exists for AA amyloidosis itself; the relevant screening paradigm is surveillance of known high-risk populations — i.e., periodic proteinuria/SAA monitoring in patients with established FMF, TRAPS, CAPS, MKD, or long-standing RA, to detect amyloid nephropathy early enough for effective intervention.

11. Outcome/Prognosis

Survival and Mortality

Historical/untreated natural history: progression to renal failure and early death without effective control of the underlying inflammatory driver (PMC11219434).
Dialysis-dependent AA amyloidosis: poor survival — reported ranges from as low as 15% survival at 31.8 months up to 51% at 5 years, reflecting historically poor outcomes on dialysis alone, worsened by cardiovascular comorbidity and hypotension-prone dialysis tolerance.
Historical kidney transplant outcomes: 10-year patient and graft survival as low as 62.3% and 56.4%, respectively (older cohorts).
Contemporary kidney transplant outcomes (French multicenter cohort, AJKD 2023, PMID:37741608): substantially improved — 94.0% patient survival at 1 year, 85.5% at 5 years; overall graft survival 75.8% at 5 years — now comparable to outcomes for diabetic nephropathy transplant recipients. CRP level at time of transplantation was independently associated with both patient and graft survival, underscoring the importance of inflammatory control at the time of transplant.
Post-transplant amyloid recurrence: histologically confirmed recurrence in AA amyloid grafts occurs in 5.8% at a median 23.5 months, associated with elevated SAA but (in this cohort) not independently associated with worse outcomes.
Mortality after transplant remains elevated primarily due to cardiovascular involvement, underscoring the importance of pre-transplant cardiac assessment.

Morbidity and Function

Principal morbidity burden derives from progressive CKD/nephrotic syndrome (edema, malnutrition from proteinuria, dyslipidemia, hypercoagulability) and — where present — chronic refractory diarrhea causing malabsorption and weight loss. No AA-amyloidosis-specific validated disability/QoL outcome measure was identified (general CKD/dialysis QoL literature applies but is not amyloid-specific).

Prognostic Factors

Baseline renal function at diagnosis/treatment initiation — earlier intervention (creatinine <1.5 mg/dL) improves renal prognosis with anti-TNF therapy specifically.
Degree and durability of SAA suppression achieved by treatment — the single most consistently reported prognostic biomarker; sustained near-normalization of SAA correlates with amyloid regression, organ function stabilization/improvement, and reduced mortality.
CRP at time of kidney transplantation — independently prognostic for both patient and graft survival.
Cardiovascular comorbidity — the dominant driver of excess mortality among successfully transplanted patients.

12. Treatment

General Principle

"The mainstay of treatment is targeted at managing the underlying pathogenic mechanisms by suppressing the cytokine-induced production of SAA protein by the liver" (PMC11219434) — i.e., AA amyloidosis treatment is fundamentally treatment of the causal inflammatory disease, not a disease-specific anti-amyloid drug (with the partial exception of the investigational agents below). Treatment is explicitly time-sensitive: delayed control cannot prevent deposition that has already occurred, though it can halt further deposition and, when SAA is durably suppressed, permit measurable regression.

Pharmacotherapy — Anti-Inflammatory/Immunomodulatory (the primary treatment class)

Colchicine (CHEBI:3532) — NCIT:C743 (Colchicine) — first-line, foundational therapy for FMF; suppresses inflammasome activation and IL-1β production; long-term compliance data (1.7% vs. 48.9% proteinuria at 11 years) constitute the strongest available prevention evidence in this disease area. NCIT treatment term: NCIT:C15986 (Pharmacotherapy) with therapeutic_agent CHEBI:3532.
Anti-TNF-α agents (e.g., etanercept, infliximab, adalimumab) — retrospective series show variable results: amyloidosis progressed in 46.7%, stabilized in 33.3%, and proteinuria regressed in 20% of a 15-patient cohort over 10 months; a larger prospective 36-patient, 5-year study found >50% proteinuria reduction in more than half of patients. NCIT class term: NCIT:C20401 (Monoclonal Antibody) or specific agent terms (e.g., NCIT:C1873 Infliximab, NCIT:C1656 Etanercept, NCIT:C1420 Adalimumab).
Anti-IL-6 (tocilizumab) (CHEBI/NCIT:C82595 Tocilizumab) — shown in a 42-patient retrospective analysis to be superior to anti-TNF agents for decreasing SAA, improving kidney function, and suppressing disease activity; "whole-cohort median pre-treatment SAA fell from 70 to 4 mg/L within 10 days of the first dose," sustained over 23 months of follow-up (PMID:26120866). Also effective in the rare autosomal-dominant SAA1-promoter-mutation hereditary form.
IL-1 inhibitors — anakinra (NCIT:C1857), canakinumab (NCIT:C74003), rilonacept — effective in monogenic autoinflammatory disease (FMF, CAPS/NLRP3-AID, TRAPS, MKD) and in colchicine-resistant/-intolerant FMF; an 11-patient anakinra series and additional canakinumab data showed benefit, including regression of proteinuria with daily anakinra in some patients; IL-1 blockade is specifically recommended for colchicine-resistant FMF-associated amyloidosis.
Combination/sequencing strategy: colchicine remains first-line for FMF; biologics (anti-IL-1, anti-IL-6, or occasionally anti-TNF) are reserved for colchicine-resistant/intolerant FMF or for the primary rheumatic/inflammatory diseases (RA, JIA, vasculitis) driving non-FMF AA amyloidosis.

Experimental / Investigational (targeting amyloid deposition directly)

Eprodisate (Fibrillex) (NCIT — investigational small molecule, glycosaminoglycan mimetic) — a Phase II/III RCT (183 patients, 27 centers, 24 months, NEJM 2007, PMID:17554116) found the composite renal-progression/death endpoint occurred in 27% (eprodisate) vs. 40% (placebo), hazard ratio 0.58 (95% CI 0.37-0.93), and creatinine clearance decline was slower (10.9 vs. 15.6 mL/min/1.73m²/year); however, the drug did not receive regulatory approval, and subsequent evaluation did not confirm sufficient benefit for approval — "the trial failed to reach primary endpoints [in some analyses] and the substance has not been approved."
Miridesap (CPHPC) + anti-SAP monoclonal antibody (dezamizumab) — a two-step approach to deplete circulating serum amyloid P component and then clear residual tissue-bound SAP-amyloid complexes with a therapeutic antibody; "safely triggered clearance of amyloid deposits from the liver and some other tissues" in early trials (NEJM 2015, PMID for the anti-SAP antibody paper: 26221758), but development was discontinued after fatal cardiac arrhythmia adverse events in a later oral-formulation study.
Antisense oligonucleotides (ASOs) targeting SAA — reduced amyloid deposition in animal models; not yet studied in humans for AA amyloidosis specifically (an analogous strategy to the ASO approach used clinically in ATTR amyloidosis — see the antisense_oligonucleotide_therapy mechanism-module pattern in the dismech schema, RNase H knockdown mechanism class).

Surgical/Interventional and Supportive Care

Renal replacement therapy — hemodialysis or peritoneal dialysis for ESKD; historically poor survival, particularly with cardiac involvement (hypotension-prone).
Kidney transplantation — the optimal treatment for AA-amyloidosis-related kidney failure in appropriately selected patients (see Section 11 for outcome data); requires pre-transplant cardiac evaluation given the cardiovascular mortality signal.
Supportive nephroprotective measures: ACE inhibitors/ARBs for proteinuria reduction, dietary sodium restriction (<2 g/day), loop diuretics for volume overload, and management of nephrotic-syndrome-associated hyperlipidemia and hypercoagulability.
Splenectomy is not a standard treatment (unlike in some historical amyloidosis contexts) — not identified as recommended in current literature reviewed.

Treatment Outcomes / Adverse Events

Anti-TNF agents in transplant recipients: better inflammation control but increased infection risk.
IL-1 inhibitors in FMF kidney-transplant recipients: longer graft survival and lower rejection rates but a paradoxically increased death rate in one 36-patient evaluation, possibly reflecting infection risk or progressive cardiovascular amyloid deposition rather than the drug itself.
Miridesap/anti-SAP antibody program: discontinued for fatal arrhythmia adverse events — an important cautionary data point for amyloid-clearance strategies generally.

Treatment Strategy / Personalized Medicine

Treatment selection is fundamentally etiology-directed (treat the causal disease) and biomarker-guided (titrate therapy to SAA/CRP normalization rather than a fixed regimen), representing a pragmatic form of "personalized medicine" already embedded in standard AA amyloidosis management, albeit driven by a conventional biomarker rather than genomic stratification.

13. Prevention

Primary Prevention

Aggressive, sustained control of the underlying chronic inflammatory/infectious disease is the principal primary-prevention strategy — most concretely demonstrated by colchicine prophylaxis in FMF, which reduces 11-year cumulative proteinuria incidence roughly 25-fold in compliant vs. non-compliant patients.
Early, effective biologic therapy for RA and other inflammatory arthritides is credited with the observed decline in AA amyloidosis incidence/relative frequency in Western cohorts over recent decades (from a historically larger share of amyloidosis cases to ~2.9% currently).
Prompt and adequate treatment of chronic infections (tuberculosis, osteomyelitis, leprosy) — the principal primary-prevention lever in regions where infection remains the dominant AA trigger.
Weight management — plausible but not rigorously trial-proven primary prevention measure given the obesity-idiopathic AA amyloidosis association.

Secondary Prevention (early detection in at-risk patients)

Routine proteinuria/urinalysis surveillance in patients with established FMF, other periodic fever syndromes, or long-standing chronic inflammatory arthritis, allowing detection of amyloid nephropathy at a subclinical/early stage when treatment intensification (colchicine dose optimization, biologic escalation) can still prevent progression.
Periodic SAA/CRP monitoring as a surrogate for cumulative amyloidogenic risk in high-risk populations.

Tertiary Prevention

Once amyloid nephropathy is established, aggressive suppression of SAA production (biologics as above) plus nephroprotective supportive care (ACE-I/ARB, sodium restriction) to slow progression to ESKD and preserve residual renal function as long as possible.

Genetic Counseling / Screening

Genetic counseling and cascade family testing are well-established for FMF and the other autosomal-dominant/recessive autoinflammatory trigger diseases (MEFV, TNFRSF1A, NLRP3, MVK), enabling early identification of at-risk relatives who can then be started on prophylactic colchicine (for FMF) before amyloid complications develop — this is arguably the single most effective genetics-driven prevention pathway in this disease area.
No population-level newborn or general-population carrier screening program specific to AA amyloidosis exists; screening operates through targeted family/ethnicity-based cascade testing in populations with elevated FMF carrier frequency.

Public Health

Reduction of the global burden of chronic infectious diseases (TB control programs, osteomyelitis prevention/early treatment) constitutes an indirect but real public-health-level AA amyloidosis prevention strategy in lower-resource settings.

14. Other Species / Natural Disease

AA amyloidosis is not unique to humans — it is one of the best-characterized examples of naturally occurring, spontaneous amyloid disease across vertebrate species, making it an unusually rich source of comparative/veterinary disease models.

Domestic dog — Chinese Shar-Pei breed (VBO term applicable): a well-documented familial predisposition to renal AA amyloidosis, with medullary interstitial deposition pattern predominating (distinct from the glomerular pattern typical in humans and Abyssinian cats); often associated with recurrent "Shar-Pei fever" episodes analogous conceptually to periodic fever syndromes. Comparative study: 91-case retrospective comparing Shar-Pei vs. non-Shar-Pei dogs (J Vet Intern Med 2012, PMID for Segev et al. study referenced above).
Domestic cat — Abyssinian and Siamese breeds: familial AA amyloidosis with breed-specific deposition patterns — predominantly glomerular in Abyssinian cats and hepatic in Siamese cats. Notably, domestic cats can develop spontaneous amyloidosis at a young age without evidence of a preceding overt inflammatory condition, an intriguing parallel to human idiopathic AA amyloidosis. A recent multi-omic study characterized Abyssinian cat renal amyloid deposits (Sci Rep 2021, PMID for Almeida-Souza/Littlewood et al. — Nature/PMC8052419), and a separate paper characterized proteinuria and candidate urinary biomarkers in feline AA amyloidosis (PMC10800178) — this is the species with the most extensive AA-amyloidosis-specific -omics dataset identified in this research, exceeding what is currently available for human AA amyloidosis.
Captive wild felids: cheetahs and black-footed cats show genetic predisposition to AA amyloidosis in captivity, an important captive-wildlife veterinary health issue.
Endangered island fox (Urocyon littoralis): a proteomic study found AA amyloidosis to be highly prevalent in this endangered species, of direct conservation-biology relevance (PMC4245998).
Cattle, mink, waterfowl, and other domestic/farmed species: AA amyloidosis is a recognized entity across additional mammalian and avian species per the Merck Veterinary Manual overview, though with less detailed molecular characterization identified in this search.
Comparative pathology / evolutionary conservation: The fundamental SAA→cleavage→misfolding→cross-β-fibril mechanism is conserved from mice through cats, dogs, and humans, though fibril structural details show species-specific "complementarity" (per the cryo-EM comparative structural work, PMC6405766) — i.e., the amyloid fold is not identical across species despite shared precursor biology.
Zoonotic potential: AA amyloidosis is not an infectious/transmissible disease in the conventional zoonotic sense — it is a protein-misfolding disorder secondary to each host's own chronic inflammatory state, not a transmissible pathogen (though the amyloid-enhancing-factor phenomenon described in Section 15 shows experimental cross-tissue and cross-individual "seeding" transferability within a species under laboratory conditions, a prion-like propagation property distinct from classical zoonosis).

15. Model Organisms

AA amyloidosis is unusual among systemic amyloidoses in having a long-established, highly efficient, and mechanistically informative rodent induction model, because SAA overexpression and amyloid deposition can be reliably triggered pharmacologically rather than requiring a transgenic construct.

Model Types and Genetics

Mouse (Mus musculus) — the dominant model species. Relevant mouse orthologs (MGI): Saa1 (MGI:98221), Saa2 (MGI:98222), Saa3 (MGI:98223) — mice, like humans, carry multiple SAA paralogs with overlapping but non-identical acute-phase/inflammatory roles.
Induced (non-genetic) models — the classical and still most widely used approach:
Casein-injection model: repeated subcutaneous/intraperitoneal injection of casein over an extended period chronically elevates SAA and induces amyloid deposition — the original and still-used chronic-inflammation-mimicking model.
Silver nitrate + AEF (amyloid-enhancing factor) model: administration of an inflammatory stimulus (e.g., silver nitrate, AgNO₃) together with intravenous AEF — a protein extract from amyloid-laden spleen or liver of a previously affected animal — produces extensive, rapid amyloid deposits within 3-5 days. AEF dramatically shortens the induction "lag phase" by providing a preformed fibrillar nucleation seed, directly demonstrating the nucleation-dependent, prion-like seeding mechanism of AA amyloidogenesis. In the standard protocol, 8-12-week-old mice receive 10 µg AEF intravenously, with deposition proceeding spleen (24-48h) → liver (3-4 days) → kidney (5-7 days), closely recapitulating the organ-involvement sequence seen clinically.
AA amyloidosis is experimentally transferable via peripheral blood monocytes between animals, further supporting a cellular (macrophage/monocyte)-mediated component of fibril seeding/propagation (PLOS ONE, referenced above).
Genetic models:
IL-1 receptor antagonist knockout (Il1rn⁻/⁻) mice — spontaneously develop AA amyloid deposition reflecting unopposed IL-1 signaling, and have been used to study deposition, clearance, and re-induction dynamics of AA amyloid (Vet Pathol 2017, Watanabe et al.).
H2/IL-6 transgenic mice — used alongside standard strains in the AEF induction protocol, providing an IL-6-overexpression genetic background that sensitizes to amyloid induction, directly modeling the human IL-6-driven SAA induction axis.
Standard Saa1/Saa2 double-knockout mice exist and have been used to probe baseline SAA physiology (e.g., altered cholesterol handling under LPS challenge) rather than as an amyloidosis model per se (loss-of-function, as expected, does not produce amyloid disease since SAA itself, not its absence, is pathogenic).
Mink (Neovison vison): AEF-based rapid induction of experimental AA amyloidosis by intravenous AEF injection has also been established in mink as an alternative model species (PMID:18266118), useful for comparative fibril-structure studies.

Phenotype Recapitulation

The induced mouse models recapitulate the key organ-deposition sequence (spleen → liver → kidney) and the cross-β amyloid fibril ultrastructure of human disease with high fidelity, and have been essential for elucidating the nucleation-dependent seeding mechanism, testing candidate anti-amyloid therapeutics (including early proof-of-concept for antisense-oligonucleotide SAA knockdown), and generating the cryo-EM fibril structures referenced in Section 6.

Model Limitations

Induced models depend on exogenous inflammatory stimuli and/or AEF seeding rather than spontaneous chronic autoimmune/autoinflammatory disease, so they may not fully capture the decades-long, genetically-modulated (SAA1 allele-dependent) human natural history, nor the specific contribution of individual human trigger diseases (RA, FMF) to the inflammatory milieu. The naturally occurring feline and canine breed-specific familial forms (Section 14) may in some respects better model the genetically-predisposed, spontaneously-arising human idiopathic/familial AA amyloidosis phenotype than the pharmacologically-induced mouse models, and — notably — the feline model currently has more extensive multi-omic characterization publicly available than human AA amyloidosis itself.

Applications

Mouse/mink induction models remain the principal tool for: (1) dissecting the nucleation-seeding mechanism of amyloidogenesis; (2) testing anti-amyloid and anti-SAA therapeutics (including the ASO strategy noted in Section 12) prior to human trials; (3) generating sufficient homogeneous amyloid tissue for structural (cryo-EM) and proteomic studies not readily obtainable from limited human biopsy material.

Resources

MGI (Saa1: MGI:98221; Saa2: MGI:98222; Saa3: MGI:98223) for mouse genetic/allele resources; no dedicated AA-amyloidosis-specific IMPC/KOMP high-throughput phenotyping line was identified in this search (SAA genes are not primary IMPC amyloidosis-phenotyping targets, consistent with the field's reliance on induced rather than constitutive-knockout models).

Summary of Suggested Ontology Terms for Knowledge-Base Curation

Table (click to expand)

Category	Suggested terms
MONDO	MONDO:0019439 (AA amyloidosis)
HPO (phenotypes)	HP:0000093 Proteinuria; HP:0000100 Nephrotic syndrome; HP:0012622 Chronic kidney disease; HP:0001919 Acute kidney injury; HP:0000083 Renal insufficiency; HP:0002240 Hepatomegaly; HP:0001744 Splenomegaly; HP:0002014 Diarrhea; HP:0002024 Malabsorption; HP:0001635 Congestive heart failure; HP:0009830 Peripheral neuropathy; HP:0000158 Macroglossia; HP:0100039 Carpal tunnel syndrome; HP:0001824 Weight loss; HP:0000969 Edema; HP:0011034 Amyloidosis (general)
GO (biological process)	GO:0006953 acute-phase response; GO:0006508 proteolysis; GO:1990000 amyloid fibril formation
GO (cellular component)	GO:0005576 extracellular region
CL (cell types)	CL:0000182 hepatocyte; CL:0000235 macrophage; CL:0000650 mesangial cell; CL:0002144 glomerular endothelial cell; CL:0000136 adipocyte
UBERON	UBERON:0002113 kidney; UBERON:0002107 liver; UBERON:0002106 spleen; UBERON:0002369 adrenal gland; UBERON:0000948 heart
HGNC/genes	SAA1 (HGNC:10513); SAA2 (HGNC:10514); MEFV (HGNC:6998); TNFRSF1A; NLRP3; MVK; IL6; IL1B; TNF
CHEBI	CHEBI:3532 colchicine
NCIT (treatments)	NCIT:C15986 Pharmacotherapy; NCIT:C743 Colchicine; NCIT:C82595 Tocilizumab; NCIT:C1857 Anakinra; NCIT:C74003 Canakinumab; NCIT:C1873 Infliximab; NCIT:C15329 Surgical Procedure (transplant context: NCIT:C15289 Organ Transplantation)